Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

43 Additionally, consistent with our preclinical research, 44 patients with dual positivity for PD‐L1 and CD8 TILs showed a trend toward a lower risk of disease progression versus those without dual positivity (HR, 0.15 [95% CI, 0.02–1.23]), although this result did not reach statistical significance and the statistical analysis was limited by the small sample size.

also in 53,322 other papers

There was a trend for patients who were double positive for PD‐L1 and CD8 to have a lower risk for disease progression than those who were not double positive (HR, 0.15 [95% CI, 0.02–1.23]; p = 0.077; Figure 4A ) but this result did not reach statistical significance.

also in 111,027 other papers